

The logo for DRI Healthcare, featuring a white plus sign icon to the left of the text "DRI HEALTHCARE" in a white, sans-serif font.

DRI HEALTHCARE

# Advancing Science

in the Pharmaceutical and  
Biotechnology Sector

December 2025

# Disclaimer

This presentation has been prepared by DRI Healthcare Trust (“DRI Healthcare”). Established as an unincorporated open-ended trust in Ontario, Canada, and publicly trading since its 2021 IPO, DRI Healthcare is a global leader in providing financing to advance innovation in the life sciences industry.

## **Cautionary Note Regarding Forward-Looking Information**

This presentation, including responses to questions related thereto, may contain “forward-looking information” within the meaning of, and made pursuant to the “safe harbor” provisions of, Canadian provincial securities laws. Statements that contain forward-looking information are predictive in nature, depend upon or refer to future events or conditions, and include, but are not limited to, statements which reflect management’s current opinions, estimates and assumptions regarding the operations, business, investment opportunities, the profitability and availability of royalty investments, results, performance, financial position and compounding of cash flow, expected financial results, priorities, objectives, strategies, prospects, pipeline, capital management and both short- and long-term outlook of DRI Healthcare and its subsidiaries, which are based on management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate and reasonable in the circumstances. Statements containing forward-looking information are typically identified by words such as “guidance,” “target,” “project,” “assumes,” “seek,” “objective,” “outlook,” “commitment,” “believe,” “expect,” “will,” and other similar expressions.

Despite careful consideration and review of the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct, and undue reliance should not be placed on such statements. Forward-looking information is subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results to materially differ from those depicted or implied by such information, including but not limited to the risk factors or assumptions identified in DRI Healthcare’s most recent Management’s Discussion and Analysis (“MD&A”), under “Risk Factors” in DRI Healthcare’s most recent Annual Information Form, and in DRI Healthcare’s other filings with Canadian securities regulators available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

The forward-looking information contained in this presentation represents management’s expectations as of the date of this presentation, and are subject to change after such date. Except as may be required by applicable securities laws, DRI Healthcare does not undertake any obligation to update or revise any statement containing forward-looking information in this presentation, whether as a result of new information, future events or otherwise.

## **Non-GAAP Measures and Ratios**

This presentation also makes reference to certain non-GAAP financial measures including Total Cash Receipts, Normalized Total Cash Receipts, Total Cash Royalty Receipts and Adjusted EBITDA, and certain non-GAAP ratios including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized measures under the International Financial Reporting Standards (“IFRS”) and are therefore unlikely to be comparable to similar financial measures disclosed by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of DRI Healthcare’s financial performance from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of financial information reported under IFRS. See “Financial Review: Non-GAAP Financial Measures” in the MD&A, which includes a reconciliation of IFRS to non-GAAP measures, such reconciliation being incorporated by reference herein.

All dollar figures in this presentation are stated in U.S. dollars unless otherwise indicated.



# Executive Summary


DRI Healthcare is a pioneer in pharmaceutical royalty monetization

DRI Healthcare excels at sourcing, analyzing and executing strategic royalty acquisitions of growing assets. We provide capital to parties along the biopharmaceutical value chain to help fund the future of innovation.

We hold a diversified portfolio of interests in drugs that address significant unmet needs, are marketed by leading biotech or pharma companies and are backed by robust intellectual property and regulatory protection.

# Pharmaceutical Royalty Model

DRI Healthcare sources deals from all parties along the drug development value chain



Each constituent sells royalties for different reasons

## Inventors

sell royalties for tax planning and philanthropic reasons

## Academic institutions

sell royalties to offset budget shortfalls or to fund large capital projects

## Drug developers

sell royalties to fund R&D programs or divest a non-core asset

## Drug marketers

create synthetic royalties as an alternative form of non-dilutive financing

# Our Competitive Advantages

## 1 Seasoned team

Specialized investment professionals with life science backgrounds and advanced business and science degrees

## 2 Disciplined capital allocation

Robust investment criteria that have resulted in strong returns

## 3 Proactive sourcing

Proprietary database tracking royalties on more than 2,500 drugs combined with deep industry relationships

## 4 Strong execution

Fundamental ground-up diligence on opportunities to execute high-quality transactions

# Track Record of Delivering Growth and Value

Transition from private equity funds to a public entity facilitates longer-term value creation

	NEW ROYALTIES	SIGNIFICANT TRANSACTIONS
<b>DRI Healthcare Trust</b> 2021 - present <i>Public entity</i>	<b>16 &amp; 1 Loan</b> valued at <b>\$1.6B<sup>1</sup></b>	
<b>DRUG ROYALTY III</b> 2013 – 2018 <i>Private equity fund</i>	<b>15</b> valued at <b>\$586M</b>	
<b>DRUG ROYALTY II</b> 2009 – 2013 <i>Private equity fund</i>	<b>27</b> valued at <b>\$730M<sup>2</sup></b>	
<b>DRUG ROYALTY I</b> 2006 – 2008 <i>Private equity fund</i>	<b>19</b> valued at <b>\$645M</b>	

1. Includes \$430 million in potential additional deployment in milestones as at December 31, 2025.  
 2. Includes \$82 million in capital deployed via co-investments through RMF 2 Co-Investment Fund.

# Diversified, Risk-mitigated Portfolio

Provides large pharmaceutical company characteristics without traditional pharma risks and costs

2021

Initial public offering

16

Royalty acquisitions

\$1.26B<sup>1</sup>

Capital deployed

7,500+

Royalty opportunities in proprietary database

For the twelve months ended December 31, 2025

\$199M

Total Income

84%


Adjusted EBITDA Margin<sup>2</sup>

\$165M

Adjusted EBITDA<sup>2</sup>

\$2.26

Adjusted Cash Earnings per Unit<sup>2</sup>



Therapeutic area allocation based on net book value calculated as at December 31, 2025

1. Deployment includes \$115M in near-term milestones associated with the Viridian transaction.

2. Adjusted EBITDA and Adjusted Cash Earnings per Unit are non-GAAP measures and Adjusted EBITDA Margin is a non-GAAP ratio. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.

3. Based on 2024 sales.

# Focused on Closing Accretive Transactions

Completed sixteen royalty transactions since IPO totaling up to \$1.6 billion, with \$1.26<sup>1</sup> billion deployed to date

	INVESTMENT THESIS	TRANSACTION SIZE	
	Pre-approval asset with long-dated cashflows, extending overall portfolio duration	\$55 million upfront payment + up to \$245 <sup>1</sup> million in potential milestones	
	Pre-approval asset with high conviction of approval plus PIPE investment	\$127 million <sup>2</sup> + up to \$57 million in potential milestone	
	Provides predictable cash flows with potential for upside optionality and limited risk	\$57 million	
	Only approved product for acid sphingomyelinase deficiency (“ASMD”) with strong IP protection and long duration	\$30 million + up to \$26.5 million in potential milestones	\$13.25 million <sup>3</sup> + up to \$32.5 million in potential milestones
	Uncapped transaction on established product providing cash accretion	\$125 million	Up to \$170 million <sup>4</sup>
	Newly approved and first in class oncology product with uncapped growth potential	\$85 million	\$140 million <sup>5</sup>
	High-quality oncology product with strong growth potential	Up to \$135 million <sup>6</sup>	\$66 million <sup>7</sup>
	Newly approved Diabetes product with long-term cash flows and growth potential	Acquisition: \$100 million Sale: \$210 million	
	High-quality oncology product with multiple pipeline indications	\$35 million + \$10 million potential milestone	
	Hematology and ophthalmology products with long-term horizon and attractive growth prospects	\$28.2 million <sup>8</sup> + \$4 million potential milestone	

1. Includes \$115 million in near-term clinical and regulatory milestone payments 2. Includes \$22 million optional payment to KalVista. 3. Represents a second royalty on Xenpozyme acquired from HLS Therapeutics Inc. 4. Represents the expansion of the royalty entitlement on the US net sales of Omidria from Omeros Corp. 5. Represents a second royalty on Orserdu acquired from Radius Health, Inc. (Radius”) and includes the \$10 milestone payment to Radius. 6. Includes \$50 million secured loan made to CTI BioPharma (“CTI”), \$60 million royalty acquired from CTI and \$6.5 million milestone payment made to CTI. The conditions required for the second milestone payment of \$18.5 million were not met by the end of the third quarter of 2023 and the additional milestone payment was not made. CTI repaid its loan in full and the related credit agreement was terminated. 7. Represents a second royalty on Vonjo acquired from S\*Bio Pte Ltd. 8. Includes \$24.5 million royalty and \$3.7 million royalty acquired from a separate counterparty.




**DRI** HEALTHCARE

Attractive  
Market

# Long-term Drivers Support Royalty Financing Growth


Growing capital needs to develop novel drugs bolsters our pipeline

Five Year Forward Projected Pipeline Value (\$B)<sup>1</sup>




- New modalities
- Molecular diagnostics
- Data science

Projected Worldwide Biopharma R&D Spend (\$B)<sup>2</sup>



- Pace of innovation
- Complex modalities
- Real-world outcomes

Projected Worldwide Medicine Spend (\$B)<sup>3</sup>



- Specialty medicines
- Aging population
- Emerging markets

1. The five-year forward pipeline value is defined as the projected pipeline value five years in the future; for example, \$263 billion is the projected 2028 revenue from all pipeline products as of 2023. Source: Boston Consulting Group, New Drug Modalities 2025, October 2025.


2. Source: Evaluate Pharma World Preview 2025: Pharma Growth Steady Amid Turbulent Seas and Rising China, June 2025.

3. Source: IQVIA: The Global Use of Medicines Outlook through 2029, June 2025.


# Current State of the Biotech Market

Lack of equity market funding makes royalty financing very attractive

Biotech IPOs<sup>1</sup>



Biotech Equities Performance<sup>2</sup>



Rapid expansion of biotech market with >500 IPOs in last 10 years

Struggling equity capital markets for biotechs



1. Source: FactSet, Jefferies Biotechnology IPO Screens, September 2025.

2. Source: FactSet as of September 30, 2025. See "Appendix B - Industry Metrics" at the end of this presentation.

# Biotech's Limited Cash Reserves Highlight Opportunities for Royalty Financing<sup>1</sup>

60% of unprofitable NASDAQ-listed biotechs are estimated to have <2 years of cash

Cash runway for unprofitable NASDAQ listed biotechs with market cap >\$25 million



1. Source: BioCentury, Bearing down in a turbulent market, BioCentury's 2Q25 Public Markets Preview, April 2025.



**DRI** HEALTHCARE

Strong  
Execution

# 2025 Financial Highlights

Total Cash Receipts<sup>1</sup>

**\$196.4 million**

↑ 3% over 2024

Total income

**\$198.6 million**

↑ 6% over 2024

Adjusted EBITDA<sup>1</sup>

**\$165.0 million**

↑ 5% over 2024

Adjusted EBITDA Margin<sup>1</sup>

**84%**

Adjusted Cash Earnings per Unit<sup>1</sup>

**\$2.26**

Declared Cash Distributions per Unit

**\$0.40**


1. Total Cash Receipts and Adjusted EBITDA are non-GAAP measures. Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit are non-GAAP ratios. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.

# Robust Diversified Portfolio


Portfolio currently consists of 29 royalty streams on 23 products

No individual product accounts for more than **25%** of net book value<sup>1</sup>

By therapeutic area<sup>1</sup>



By product<sup>1</sup>



1. Based on net book value calculated as at December 31, 2025. Casgevy is presented at fair value.

# Portfolio Performance

Portfolio assets show continued growth

(millions of U.S. dollars)	THERAPEUTIC AREA	Total Cash Royalty Receipts <sup>1</sup>	Net Book Value <sup>2</sup>
		LTM 12/31/2025	12/31/2025
	Hematology	5.0	57.3
	Immunology	0.8	120.2
	Hematology / Ophthalmology	4.9	19.4
	Ophthalmology	6.2	5.8
	Endocrinology	1.0	-
	Ophthalmology	34.1	153.5
	Dermatology	4.6	3.0
	Oncology	80.2	176.3
	Oncology	3.6	3.8
	Neurology	15.2	56.0
Veligrotug/elegrobart	Ophthalmology	-	57.0
	Hematology	14.1	83.9
	Lysosomal Storage Disorder	4.4	35.9
	Oncology	12.6	31.8
	Oncology	3.9	24.0
	Oncology	3.8	6.8
Other Products <sup>5</sup>	Various	2.0	0.6
<b>TOTAL</b>		<b>196.4</b>	<b>777.8</b>

1. Total Cash Royalty Receipts is a non-GAAP measure. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.

2. The total net book value only refers to the net book value of intangible royalty assets only and does not include the net book value of Casgevy, which is classified as a financial royalty asset.

3. Cash receipts for Orserdu II and Orserdu I for the year ended December 31, 2025 include \$17,593 and \$633, respectively, for reclamation of previous royalty deductions, as described on page 5 of the MD&A. Cash receipts for the year ended December 31, 2024 include milestone royalty receipts of \$2,104 from Orserdu I, \$18,939 from Orserdu II and \$5,000 from Vonjo II received in Q1 2024.

4. Cash receipts for the year ended December 31, 2024 include \$1,000 in additional cash receipts related to a one-time payment received in Q1 2024.

5. Other Products includes royalty income from certain other intangible royalty assets as well as intangible royalty assets which are fully amortized and, where applicable, the entitlements to which have generally expired. Comparative figures for royalty assets Simponi, Stelara and Ilaris are included in Other Products.

# Veligrotug and Elegrobart (VRDN-003) royalty transaction

Pre-approval asset with long-dated cashflows, extending overall portfolio duration

## Veligrotug & Elegrobart (VRDN-003)

### TRANSACTION OVERVIEW

Veligrotug granted Breakthrough Therapy Designation by the FDA for active and chronic thyroid eye disease (“TED”)

VRDN-003 in phase 3 clinical trials with results expected first half of 2026

\$55 million up-front purchase price

Entitled to a tiered royalty on annual U.S. net sales of veligrotug and VRDN-003

First royalty paid on a one-quarter lag, after first commercial sale of veligrotug

### STRONG GROWTH POTENTIAL

TED is an autoimmune inflammatory disorder of the eye socket that affects about 300,000 patients in the US

Veligrotug will be the second approved biologic treatment for TED, with the potential to improve patients’ quality of life with fewer doses and less time required for a full treatment course

If approved, VRDN-003 is expected to provide additional convenience benefits with a low-volume autoinjector designed for self-administration, planned for commercial launch

# Ekterly Royalty Transaction

First pre-approval royalty acquisition and PIPE investment highlight evolving investment strategy



## TRANSACTION OVERVIEW

Approved by the FDA in July 2025 for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

\$100 million up front purchase price plus \$5 million PIPE<sup>1</sup>

Paid \$22 million as an optional one-time payment to the marketer in July 2025, which increased the first tier royalty rate

Entitled to a tiered royalty on worldwide net sales

Royalties collected on a quarterly basis beginning in Q4 2025

## STRONG GROWTH POTENTIAL

Potential \$57 million sales-based milestone if annual net sales reach \$550 million before January 1, 2031

Royalties are anticipated to be collected through at least 2041

1. Private investment in public equity.

# Casgevy Transaction

Novel deal structure offers predictable annual cash flows plus potential additional payments



## TRANSACTION OVERVIEW

Approved by the FDA in December 2023 for the treatment of sickle cell disease (“SCD”) and in January 2024 for the treatment of transfusion-dependent beta thalassemia (“TDT”), and approved by the EMA in February 2024 for both indications

\$57.0 million up front purchase price

Entitled to receive specific payments based on a sublicensing agreement for the Cas9 gene-editing technology for Casgevy

Payments collected annually in Q1

Deal completed in October 2024

## STRONG GROWTH POTENTIAL

Potential additional annual sales-based milestones in every year

Entitled to receive a mid-double-digit percentage of a \$50 million contingent payment


Only approved gene-edited cell therapy for SCD and TDT

Payment streams run until 2034

# Strong Cash Generation

Cash available to drive portfolio growth and maintain distributions to Unitholders

Adjusted EBITDA<sup>1</sup> for the Last Twelve Months Ended December 31, 2025 (millions)



LTM Adjusted EBITDA Margin<sup>1</sup>

84%



LTM Adjusted Cash Earnings per Unit<sup>1</sup>

\$2.26

1. Adjusted EBITDA and Normalized Total Cash Receipts are non-GAAP financial measures. Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit are non-GAAP ratios. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.

2. Operating expenses include Other operating expenses, G&A, Unit-based compensation, Deal investigation and research expense and all other relevant expenses.



**DRI** HEALTHCARE

Positioned  
for Growth

# 2025 Guidance Lookback

## Fiscal 2025 Guidance

For FY 2025, DRI Healthcare communicated its guidance using the following framework:

	2025 Guidance	
<b>Capital deployment target</b>	More than \$1.25 billion over 5 years from IPO <sup>1</sup>	<input checked="" type="checkbox"/> On a committed basis, incl. near-term contingent milestone payments, DRI Healthcare delivered against target of deploying \$1.25 billion over five years
<b>Income from royalty assets</b>	\$172 – 182 million <sup>2</sup>	<input checked="" type="checkbox"/> Above range, at \$188.7M in FY 2025
<b>Sustainable cash generation</b>	High single digit royalty income CAGR through 2030 <sup>3</sup>	<input checked="" type="checkbox"/> Currently tracking at double-digit CAGR

1. Includes near-term milestones of \$115 million as it relates to the Viridian transaction.  
 2. Includes Royalty Income plus the change in fair value of financial royalty assets, excluding milestones and any new transactions.  
 3. Includes Royalty Income plus the change in fair value of financial royalty assets, excluding any new transactions.

# 2026 Guidance & Long-Term Growth Agenda

## 2026 Guidance

**Adjusted EBITDA (\$)**

**\$157 to \$162 Million<sup>1</sup>**

Reported 2025 Adjusted EBITDA	\$164.9M
Adjustment for non-recurring back-dated royalty recoveries	\$(15.7)M
Run rate 2025 Adjusted EBITDA baseline for comparative purposes	\$149.2M

## Multi-Year Aspiration through 2030<sup>2</sup>

**Capital Deployment Target Over 5 Years (2026 – 2030)**

**\$800 Million to \$1 Billion**

**Adjusted EBITDA Growth Rates (%)**


**Low Teens CAGR 2026 to 2030<sup>1</sup>**

1. Adjusted EBITDA guidance is based on a 2025 Adjusted EBITDA run rate which has been adjusted to remove a \$15.7M impact of non-recurring back-dated royalty recoveries received in the first quarter of 2025 related to Orserdu. The table above outlines the adjustment from reported 2025 Adjusted EBITDA to the run-rate Adjusted EBITDA for 2025 which will form the comparative baseline for 2026 Adjusted EBITDA guidance.

2. The multi-year aspiration does not constitute guidance or outlook but rather are provided for the purpose of assisting the reader in measuring progress toward DRI Healthcare's growth objectives.

# Proactive Sourcing Provides Competitive Advantage

Our strong relationships and proprietary processes generate exclusive deal flow



# Rigorous Due Diligence Process

## Deal Launch

- Appointment of internal multi-disciplinary deal team
- Individualized diligence plan and deal size considerations
- Proactive assessment of deal risks
- Strategic engagement of external consultants

### SciMed Review

- MoA and preclinical review
- Review of key clinical trials
- In-depth clinical and patient data analysis
- Probability of success determination
- Regulatory environment analysis
- Targeted KOL research and interviews

### IP and LOE

- Comprehensive internal IP assessment of
  - patent coverage
  - validity and enforceability
  - freedom to operate
  - LOE
  - litigation risk
- Specialized IP review and opinions provided by external counsel

### Commercial Assessment

- Primary and secondary market research
- Detailed market models and third-party forecasts
- Competitive landscape evaluation, including product cost comparisons
- Commercial bankruptcy risk
- Marketer assessment and strategy review
- Reimbursement analysis

### Legal

- Customized deal structure by experienced legal team
- Underlying agreement review, including licensing agreements
- Bankruptcy and overall risk assessment
- Tax implications
- Legal opinions and additional risk analysis by external counsel

#### Glossary

**IP** – intellectual property. **KOL** – key opinion leaders. **LOE** – loss of exclusivity. **MoA** – mechanism of action.

# DRI HEALTHCARE

Robust pipeline of over  
**\$3 Billion**  
in potential opportunities<sup>1</sup>



Address important unmet needs with life-changing therapies for patients

---



Marketed by leading biotech or biopharma companies

---




Provides strong intellectual property and regulatory protection


<sup>1</sup>. As of December 31, 2025. Represents the aggregate value of potential opportunities under active evaluation by our investment team.

# Compounding Cash Flows Increase Growth Potential

Enables future acquisitions and delivers value for Unitholders



## Virtuous cycle of growing returns and reinvestment




1. The above chart is for illustrative purposes only to depict the effect of reinvesting cash flow over time. The chart was generated using a typical deal cash flow profile based on a historical analysis of our internal database of royalty transactions. Key assumptions include original transaction funded with a mix of debt and equity, with interest rate expense and other operating costs factored in.

2. Total Cash Receipts and Adjusted EBITDA are non-GAAP measures. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.

# Growth Opportunities from Existing Assets<sup>1</sup>

Additional indications have potential to enhance royalty streams



1. As of December 31, 2025. Growth opportunities represent ongoing trials for some of the products in our portfolio to be used in additional indications. We do not make any representations that such trials will be ultimately successful, or regarding our performance if such trials were to be successful.

# Committed to ESG Practices

Striving to deliver value to our stakeholders, our community, and society as a whole



## Environmental

Building a platform  
for sustainability

- Review of our partners' sustainability practices
- Head office located in a Gold LEED-certified building
- Committed to waste reduction
- Employee environmental training and awareness



## Social

Valuing diversity and  
community support

- Highly diverse and inclusive team
- Balanced gender representation
- Employee paid time off for charitable volunteering
- Professional development and career advancement
- Corporate giving and donations



## Governance

Accountability and integrity  
as core values

- Strong governance practices and policies
- Diverse and majority independent Board
- Board oversight of ESG and risk management
- Active Unitholder engagement
- Robust cybersecurity
- Whistleblower policy

**DRI** HEALTHCARE

Key  
priorities



Efficient Execution & Disciplined  
Expense Management

---



Strengthening Asset Risk Framework

---



Disciplined Capital Allocation

---



Focus on long-term, sustainable growth  
generating strong Unitholder returns

# DRI Healthcare Units are Undervalued Relative to Royalty Peers

Valuation comparisons highlight underlying value<sup>1</sup>

	PRICE / BOOK	PRICE / OPERATING CASH FLOW <sup>2</sup>	DIVIDEND YIELD
DRIHEALTHCARE	1.4x	8.4x	3.5%
ROYALTY PHARMA	2.4x	8.6x	2.4%
XOMA	6.4x	NA	0.0%
Ligand	4.2x	64.2x	0.0%
Franco-Nevada	6.6x	36.4x	0.7%
WHEATON PRECIOUS METALS	6.7x	37.6x	0.6%

1. Information sourced from company filings as of December 31, 2025.

2. DRI Healthcare's cash flow calculated as Cash Flow from Operating Activities plus Cash Interest Received less Cash Interest Paid.

# DRI HEALTHCARE

## Investment Highlights



Founded in 1989, **DRI Healthcare is a pioneer and a global leader** in healthcare royalty investing



We believe we are well positioned to capitalize on generational industry growth delivering attractive **uncorrelated cash flows**



**Diversified portfolio** of products by therapeutic area and marketer



Potential for high margin value opportunity on **self-liquidating asset** class generating quarterly cash flows



Decades-long industry relationships and highly specialized investment capabilities create **strong barriers to entry**

 DRI HEALTHCARE

Contact us

 [ir@drihealthcare.com](mailto:ir@drihealthcare.com)



Appendix A  
Deal Summaries

# Omidria Expansion Transaction

Highly accretive transaction with both near and long-term cash flow generation



## TRANSACTION OVERVIEW

Approved by FDA in May 2014 and by the EMA in July 2015 for intracameral use during cataract surgery or intraocular lens replacement to maintain pupil dilation and reduce postoperative pain

\$115 million up front purchase price plus up to \$55 million in potential milestones

30% royalty rate on US net sales through December 31, 2031

Deal completed in February 2024

## STRONG GROWTH POTENTIAL

Replaces annual structured caps from original Omidria transaction, giving upside exposure to sales growth

Mature product brings stable sales history and predictable growth

Anticipated significant contribution to cash flows from 2024 through 2031

Material cash flows anticipated to exceed original Omidria transaction's annual caps of \$13 – \$27.5 million

# Orserdu Royalty Transactions

Uncapped royalties on long-duration asset



## TRANSACTION OVERVIEW

### **Orserdu I**

\$85 million upfront purchase price

Mid-single digit tiered royalty on worldwide net sales

Deal completed in June 2023

### **Orserdu II**

\$130 million upfront plus potential \$10 million milestone payment, which was paid in January 2025

Low to high single digit tiered royalty on worldwide net sales

Deal completed in August 2023

Royalties collected on a one-quarter lag

## STRONG GROWTH POTENTIAL

Approved by the FDA in January 2023 and the EMA in September 2023 for advanced/metastatic breast cancer patients with ESR1 mutations

Significant progression free survival benefit over standard of care with limited side effects and convenience of oral administration

We are entitled to receive regulatory and sales-based incoming milestone payments in addition to royalties

# Vonjo II Royalty Transaction

Second royalty on Vonjo increases exposure to long duration high-quality asset



## TRANSACTION OVERVIEW

Approved by the FDA in February 2022 as the only treatment for myelofibrosis with severe thrombocytopenia

\$66 million purchase price for a tiered royalty on worldwide net sales

We are entitled to receive up to \$107.5 million in incoming milestone payments

Deal completed in July 2023

## STRONG GROWTH POTENTIAL

First year of sales strongly exceeded analyst consensus estimates

\$6.5 million payment made to CTI in January 2023 for achieving sales milestone on Vonjo I royalty

In June 2023, Sobi acquired CTI for \$1.7 billion

# Tzielid Royalty Transaction

Proceeds reinvested to generate compound effects for Unitholders



## ACQUISITION FROM MACROGENICS

Approved by the FDA in November 2022 for the treatment of stage 2 Type 1 diabetes

\$100 million up front purchase price for a single digit royalty on worldwide net sales

Up to a \$50 million potential milestone tied to the successful advancement of treatment of newly diagnosed or recent-onset Type 1 diabetes by 2028

Additional \$50 million potential milestone payment based on exceeding certain sales thresholds

Deal completed in March 2023

## SALE TO SANOFI

Sanofi announced agreement to acquire Provention Bio days after our-acquisition of the royalty

\$210 million upfront sale for our-royalty entitlement

Sanofi is now obligated to pay the two \$50 million milestones to Macrogenics if they are achieved

Deal completed in April 2023

# Xenpozyme I Royalty Transaction

Long duration product with strong IP protection anticipated to generate high multiple on invested capital



## TRANSACTION OVERVIEW

Approved by the EMA in June 2022 and by the FDA in August 2022 for the treatment of ASMD

\$30 million up front purchase price

Approximately 1% royalty on worldwide sales

Royalties collected semi-annually

Deal completed in November 2022

## STRONG GROWTH POTENTIAL

\$26.5 million in potential milestone payments based on cumulative royalties received

First and only approved product for the treatment of ASMD, also known as Niemann-Pick disease

Royalties are expected to expire in Q4 2036

# Xenpozyme II Royalty Transaction

Second royalty on long-term asset further increases portfolio duration



## TRANSACTION OVERVIEW

Approved by the EMA in June 2022 and by the FDA in August 2022 for the treatment of ASMD

\$13.25 million up front purchase price

Approximately 1% royalty on worldwide sales

Entitled to receive all royalties up to \$6.3 million in royalty receipts per calendar year, with an economic sharing agreement for all royalty receipts above this amount

Royalties collected semi-annually

Deal completed in June 2024

## STRONG GROWTH POTENTIAL

\$32.5 million in potential milestone payments based on Xenpozyme achieving certain annual net sales thresholds

First and only approved product for the treatment of ASMD, also known as Neimann-Pick disease

Royalties are expected to expire in Q4 2036

# Omidria I Royalty Transaction<sup>1</sup>

Substantial near-term cash flows with long-term structural growth anticipated



## TRANSACTION OVERVIEW

Approved by the FDA in May 2014 and by the EMA in July 2015 for intracameral use during cataract surgery or intraocular lens replacement


\$125 million up front purchase price, subject to annual cash receipt caps

Marketed by Rayner Surgical with royalties collected monthly

Deal completed in October 2022

## STRUCTURED GROWTH

Annual Royalty Receipt Caps (\$M)



1. This deal was amended as described in the *Omidria expansion transaction* slide earlier found in this presentation.

# Zejula Royalty Transaction

Multiple indications in development represent a pipeline in a product



## TRANSACTION OVERVIEW

Approved by the FDA in March 2017 and by the EMA in November 2017 for the treatment of ovarian cancer

\$35 million up front purchase price

0.5% net royalty on worldwide net sales by GSK

Royalties collected on one-quarter lag

Deal completed in September 2022

## STRONG GROWTH POTENTIAL

\$10 million milestone payment if Zejula is approved by FDA for the treatment of endometrial cancer by December 31, 2025

In development for metastatic castrate sensitive and resistant prostate cancer, endometrial cancer, HER2-breast cancer, and non-small cell lung cancer

Royalties are expected to expire in Q2 2033

# Empaveli Royalty Transaction

Long-term horizon and attractive growth prospects



## TRANSACTION OVERVIEW

Empaveli: Approved by the FDA in May 2021 and by the EMA in December 2021 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (“PNH”)

Syfovre: Approved by the FDA as the first and only treatment for Geographic Atrophy in February 2023

\$28.2 million purchase price<sup>1</sup> plus a \$4.0 million potential milestone payment

<1% royalty on worldwide net sales up to \$500 million per annum

Deal completed in July 2022

## STRONG GROWTH POTENTIAL

Represents a significant advancement in the standard of care for PNH

In development for pipeline indications including Cold Agglutinin Disease and C3 Glomerulopathy

Option to increase the annual sales cap to \$1.1 billion in return for a one-time payment of \$21 million<sup>2</sup>

1. Includes \$24.5 million royalty acquired on July 20, 2022 and \$3.7 million royalty acquired from a separate counterparty on April 3, 2023. 2. The option expired as of June 1, 2023.

# Oracea Royalty Transaction

Strong cash flows generate immediate revenues



## TRANSACTION OVERVIEW

Approved by the FDA in 2006 for the treatment of Papulopustular Rosacea

\$50.5 million purchase price for royalties on worldwide sales

Deal completed in September 2021

## STRONG GROWTH POTENTIAL

It has an established commercial track record and brings immediate accretive value with substantial royalty receipts netted out of purchase price

Among leading treatment options for managing papulopustular rosacea

Two additional royalty interests acquired as part of transaction

Royalties collected on a one-quarter lag and are expected to expire in Q1 2028

# Deal Structure Case Study: CTI BioPharma / Vonjo

Proven ability to provide flexibility in deal structuring while managing risk



Pre-approval	\$50 million secured loan	→	<ul style="list-style-type: none"> <li>• Funding for Vonjo launch preparation</li> <li>• Secured loan provided downside protection if approval not granted</li> </ul>
Upon approval	\$60 million tiered royalty	→	<ul style="list-style-type: none"> <li>• Funding for Vonjo launch</li> <li>• Sliding royalty rates as annual sales increase</li> <li>• DRI Healthcare obtains higher royalty on lower tranche of annual sales</li> </ul>
Milestones by Q3 2023	Up to \$25 million <sup>1</sup>	→	<ul style="list-style-type: none"> <li>• Two potential milestones in event Vonjo sales exceeded certain thresholds by Q3 2023</li> <li>• Risk sharing for different launch curves</li> </ul>

1. A milestone payment of \$6.5 million was paid to CTI on January 25, 2023. The conditions required for the second milestone payment of \$18.5 million were not met by the end of Q3 2023 and the additional milestone payment was not made.

Appendix B  
Industry Metrics

# Industry Metrics

References in this presentation to a securities index or other benchmark are made for informational purposes only and an investment in DRI Healthcare is unlike an investment in an index of securities or the aggregate funds constituting such benchmark. The investment characteristics of such index or benchmarks may differ materially from DRI Healthcare, and an investment in DRI Healthcare is not comparable to an investment in such an index (or benchmark) or in the securities that comprise the index (or benchmark). The risk/return profile in the index or benchmark is also typically materially different from that of DRI Healthcare. DRI Healthcare does not trade in any of the securities represented in the index, and DRI Healthcare may employ leverage, hedging, and other investment strategies that may not be incorporated in the index. In addition, investing in DRI Healthcare is generally subject to expenses or allocations payable by DRI Healthcare, none of which are reflected in the index. Further, the index or benchmark is not necessarily used or selected by DRI Healthcare as an appropriate benchmark to compare relative to the performance of DRI Healthcare, but rather it is included because DRI Healthcare believes it serves as a useful point of comparison and is a well known and widely recognized index or benchmark. DRI Healthcare is not managed to track the performance of the index referenced herein.

The **S&P 500 Total Return Index** is calculated based on price changes and reinvested dividends of the S&P 500® index, which includes 500 companies in leading industries of the U.S. economy, capturing 75% coverage of U.S. equities. The index is composed almost entirely of common stocks of companies listed on the New York Stock Exchange (including NYSE Arca and NYSE Amex) and NASDAQ stock market. REITs (excluding mortgage REITs) and business development companies are also eligible for inclusion. Additions to the index must have over \$4 billion in market capitalization, a public float of at least 50%, four consecutive quarters of positive as-reported earnings, adequate liquidity and reasonable price. The S&P 500 Index is an unmanaged, market-value weighted index with each stock's weight in the index proportionate to its market value.

The **BTK Price Index** represents common stocks or American depository receipts of selected companies involved in the biotechnology industry, and listed on the NYSE, NASDAQ, NYSE MKT, or another major U.S. exchange.

The **S&P Biotechnology Select Industry®** represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.

The **SPX Index** is Standard and Poor's 500, or commonly known as the S&P 500, is an index that includes 500 leading companies and covers approximately 80% of available market capitalization.